CellSource First Quarter 2025 Earnings: JP¥2.27 loss per share (vs JP¥7.23 profit in 1Q 2024)

Simply Wall St

March 12, 2025

CellSource (TSE:4880) First Quarter 2025 Results

Key Financial Results

Revenue: JP¥849.0m (down 28% from 1Q 2024).
Net loss: JP¥45.0m (down by 132% from JP¥143.0m profit in 1Q 2024).
JP¥2.27 loss per share (down from JP¥7.23 profit in 1Q 2024).

earnings-and-revenue-growth — TSE:4880 Earnings and Revenue Growth March 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

CellSource Earnings Insights

Looking ahead, revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in Asia.

Performance of the market in Japan.

The company's shares are up 4.5% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for CellSource that we have uncovered.

If you're looking to trade CellSource, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.